Pamlab is a company focused on the future. We are looking for hard-working, motivated and optimistic individuals who would like a challenging career and are willing to contribute to the company's unparalleled commitment to providing quality products to our customers.
Pamlab prides itself on being recognized as a good place to work because we strive to provide an environment that enables employees to succeed.
Pamlab and all its subsidiaries are Equal Opportunity Employer(s).
Pamlab headquarters is located in Covington, Louisiana. The company has been in the pharmaceutical industry since 1957, over 50 years. Initially, the company introduced numerous prescription cough/cold products to prescribing physicians in Louisiana.
In 1987, the company was purchased by Samuel and Judith Camp, who recognized the need for product line expansion and professional field sales force. Over the next 10 years, the Covington, Louisiana based Pan American Laboratories grew substantially and profitably, becoming a trusted name among thousands of physicians throughout the Southeast.
Pamlab is now a fully integrated pharmaceutical company, with approximately 300 employees, specializing in prescription medical foods. Pamlab products are marketed and sold nationally.
Recently, we have expanded Pamlab to include: Pan American Laboratories and Red River Pharma.
We proudly offer a comprehensive and valuable benefits package designed to fit the needs of our employees and their families.
Pamlab Announces Agreement for Sale of Business to Nestlé Health Science. Acquisition Adds Value to Patients and Healthcare Providers in Brain Health and Metabolic Health.
Dr. Vivian Fonseca (immediate past President of American Diabetes Association) and Dr. John Anderson (incoming President of American Diabetes Association) conducted a CME for Medscape on diabetic peripheral neuropathy and the benefits of Metanx® therapy with T2D patients.
Metanx® clinical data is published in The American Journal of Medicine entitled "Metanx in Type 2 Diabetes with Peripheral Neuropathy: A Randomized Trial." Dr. Vivian Fonseca is the primary investigator of the study.
2013 annual National Sales Meeting for all Pamlab employees and sales force was held in New Orleans, LA.
Deplin® is featured in current issue of Current Psychiatry which cites Dr. George Papakostas (Mass General Hospital) research on L–methylfolate. The article is written by Dr. Drew Ramsey of Columbia University and is entitled: "Vitamin Deficiencies in Mental Health."
L–methylfolate research by Dr. George Papakostas (Mass General Hospital) and Dr Richard Shelton (Univ S Alabama) and Dr. John Zajecka (Rush University) has been published in the American Journal of Psychiatry. The title is: "L–Methylfolate as adjunctive therapy for SSRI–resistant major depression: results of two randomized, double–blind, parallel–sequential trials."
Dr. Chuck Raison (AZ), Dr. Vladimir Maletic (SC) and Dr. Rakesh Jain (TX) lead a CME course on L–methylfolate at U.S. Psych Congress in San Diego.
Dr. Andy Cutler (FL) lead a Deplin® Product Theater at NEI Conference in San Diego.
Metanx®Clinical Study has been published in the current issue of American Journal of Pharmacy Benefits entitled "Treatment Lowers the Risk of Hospitalization and Decreases Disease-Related Costs." This pharmacoeconomics study was conducted by Rolin Wade RPh, from Cerner LifeSciences of Beverly Hills will be of interest to managed care organizations.
CerefolinNAC® sponsored the Alzheimer’s Association Walk for the LA Chapter in Fontainebleau State Park.
Pamlab served as a major corporate sponsor for the inaugural ADA walk of the Northshore, LA chapter in Mandeville, LA.
Discovery Channel Profile Series featured CerefolinNAC® doctors and patients speaking about the product being used for MCI. National television broadcast and web channel broadcast.
CerefolinNAC® was a national corporate attendee at AARP National Conference in New Orleans.
Pamlab employees elected mid–year VERITAS award winners for company town hall meeting. Role model employees were recognized in 8 categories.
Metanx® clinical data is published in Diabetes Journal regarding positive research outcomes with peripheral neuropathy in Zucker diabetic fatty rats. The research was conducted at the Pennington Reasearch Center by Irina Obrosova, PhD.
Neuropathy Association sponsored a national webinar on Metanx® hosted by Dr. Allen Jacobs (MO) and Dr. Todd Levine (AZ).
Deplin® poster on new clinical data published at American Psychiatric Association conference in Philadelphia.
CDE experts Deborah Hinnen (KA) and Virginia Valentine (NM) led national webinar of Metanx® and DPN for Certified Diabetes Educators (CDE) with dLife.com.
Pamlab, Inc launches the LESS IS MORE initiative to initiate the use of digital detailing with outside sales reps and internet marketing initiatives. App development and data mart management will be done in-house.
Deplin® sponsored a national disease state awareness program entitled "Beyond the Resistance" to educate physicians on their options in treating MDD depression patients who do not adequately respond to their initial antidepressant therapy. The national initiative will take place in 38 cities over the course of six months.
Dr. Emily Clinonsky (MA) was a featured speaker for CerefolinNAC® at the American Academy of Geriatric Psychiatrists in Washington DC.
2012 annual National Sales Meeting for all Pamlab employees and sales force was held in Dallas, TX.
Wall Street Journal published a long format article on Deplin® in the January 3 issue entitled "Giving Antidepressants a Boost with a Vitamin."